Welcome to our dedicated page for Sage Therapeutic SEC filings (Ticker: SAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the clinical trial nuances buried in Sage Therapeutics’ SEC disclosures can feel like decoding neuroscience itself. Cash-burn details, FDA feedback, and insider moves often span hundreds of pages, leaving investors hunting for the data that moves SAGE’s share price.
Stock Titan solves that problem. Our AI instantly converts every Sage Therapeutics quarterly earnings report 10-Q filing, annual report 10-K simplified edition, and Sage Therapeutics 8-K material events explained post into plain-English highlights. Need real-time alerts? We stream Sage Therapeutics Form 4 insider transactions real-time so you never miss executive stock transactions. Curious about dilution risk? The platform links R&D expense trends directly to clinical program updates, while our AI narrative answers common searches like “Sage Therapeutics SEC filings explained simply” and “understanding Sage Therapeutics SEC documents with AI.”
Whether you’re tracking postpartum-depression launch metrics or comparing NMDA program spend, you’ll find every filing type in one place:
- Sage Therapeutics insider trading Form 4 transactions with easy charts
- Sage Therapeutics proxy statement executive compensation details distilled
- Sage Therapeutics quarterly earnings report 10-Q filing revenue and runway tables
- Sage Therapeutics earnings report filing analysis highlighting trial milestones
Use these insights to monitor drug-approval catalysts, spot capital-raise signals, and gauge management’s confidence. Stop sifting through PDFs and start acting on knowledge the moment the filing hits EDGAR.
Sage Therapeutics (SAGE) reported insider trading activity through a Form 4 filing for Chief Scientific Officer and Interim Head of R&D Michael C. Quirk. On June 24, 2025, Quirk disposed of 113 shares at a price of $9.22 per share through a tax withholding transaction (Code F).
The transaction was related to the vesting of 338 time-based restricted stock units (RSUs) that were originally granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan. The RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments.
Following the reported transaction, Quirk directly owns 30,461 shares of Sage Therapeutics common stock. The Form 4 was filed on behalf of Quirk by attorney-in-fact Brandon Marsh on June 26, 2025.
Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics (SAGE), reported a Form 4 filing on June 28, 2025, detailing changes in beneficial ownership.
Key transaction details:
- On June 24, 2025, Shiferman had 79 shares withheld for tax purposes at a price of $9.22 per share
- The withholding was related to the vesting of 234 time-based restricted stock units (RSUs) granted on October 28, 2021
- These RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments
- Following the transaction, Shiferman directly owns 30,950 shares of common stock
The transaction was executed under the company's 2014 Stock Option and Incentive Plan, with Brandon Marsh signing as attorney-in-fact for Shiferman on June 26, 2025.
FAQ
What is the current stock price of Sage Therapeutic (SAGE)?
What is the market cap of Sage Therapeutic (SAGE)?
What is the primary focus of Sage Therapeutics?
Which receptor systems are targeted by the company?
How does Sage Therapeutics drive its drug development?
What therapeutic areas are included in the company’s pipeline?
How does the company position itself within the competitive landscape?
What role do strategic partnerships play at Sage Therapeutics?
Can you describe the company’s approach to research and development?
How does Sage Therapeutics ensure scientific credibility?
